Abstract:Non-alcoholic fatty liver disease (NAFLD) represents a complex disorder characterized by hepatic lipid accumulation and inflammation, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and fibrosis. Emerging evidence suggests that dysregulation of the gut- liver axis plays a pivotal role in the pathogenesis and progression of NAFLD. This review comprehensively examines the bidirectional communication between the gut and liver, encompassing intestinal barrier dysfunction, gut microbiota dysbiosis, bile acid metabolism, and immune-mediated responses. We explore the mechanisms by which gut-derived factors, including microbial metabolites, lipopolysaccharides (LPS), and bile acids, influence hepatic lipid metabolism, inflammation, and fibrosis in NAFLD. Furthermore, we discuss therapeutic strategies targeting the gut-liver axis, including prebiotics, probiotics, bile acid modulators, and gut barrier enhancers, with the potential to attenuate NAFLD progression. Understanding the intricate interplay between the gut and liver in NAFLD pathogenesis offers novel insights into disease mechanisms and therapeutic opportunities for the effective management of this increasingly prevalent liver disorder. Non-alcoholic fatty liver disease (NAFLD) is a complex disorder that is characterized by the accumulation of fat and inflammation in the liver. This can range from simple steatosis to more severe conditions such as non-alcoholic steatohepatitis (NASH) and fibrosis. Research has shown that the gut-liver axis, which includes the communication between the gut and liver, plays a significant role in the development and progression of NAFLD. This comprehensive review examines the two-way communication between the gut and liver, including intestinal barrier dysfunction, gut microbiota dysbiosis, bile acid metabolism, and immune-mediated responses. We explore how gut-derived factors such as microbial metabolites, lipopolysaccharides (LPS), and bile acids can affect hepatic lipid metabolism, inflammation, and fibrosis in NAFLD. Additionally, we discuss various therapeutic strategies, such as prebiotics, probiotics, bile acid modulators, and gut barrier enhancers, that target the gut-liver axis and potentially reduce the progression of NAFLD. Understanding the complex relationship between the gut and liver in NAFLD pathogenesis can provide new insights into the disease's mechanisms and offer therapeutic opportunities for managing this increasingly prevalent liver disorder

Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD

Fecal Microbiota Transplantation in NAFLD Treatment

Mechanisms of Nonalcoholic Fatty Liver Disease Induced by Antibiotic Resistance and Evaluation of Bacteriophag-Efficacy

Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect

Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies

The gut-liver nexus: exploring gut microbiota dysbiosis in non-alcoholic fatty liver disease and its therapeutic implications

Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease

Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view

An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease

The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment

Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies

Gut microbiome and NAFLD: impact and therapeutic potential

The Gut Microbiome and Gut-Liver Axis in NAFLD

The Gut-Liver Axis in NAFLD Progression: Insights into Pathogenesis and Therapeutic Opportunities

New perspective on fecal microbiota transplantation in liver diseases

The Gut Microbiota and its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

Fecal microbiota transplantation: current challenges and future landscapes

Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?

The Molecular and Mechanistic Insights Based on Gut–Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement

Gut Microbiota in NAFLD Pathogenesis and Possible Dietary-Based Strategies